Daiichi Sankyo Company, Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a DSKYF research report →
About the company
Daiichi Sankyo Company, Limited operates as a global pharmaceutical powerhouse, dedicated to the research, development, manufacturing, and worldwide commercialization of a wide array of medicinal products. The company boasts an extensive portfolio of therapeutics spanning numerous health conditions. In oncology, its offerings include trastuzumab deruxtecan, an innovative anti-HER2 antibody-drug conjugate for cancer treatment, alongside agents such as gefitinib for malignant tumors, bicalutamide for prostate cancer, and tamoxifen for breast cancer.
- CEO
- Hiroyuki Okuzawa
- IPO
- 2008
- Employees
- 18,726
- HQ
- Tokyo, JP
Price Chart
- Market Cap
- $28.64B
- P/E
- 18.87
- P/S
- 2.27
- P/B
- 2.92
- EV/EBITDA
- 13.82
- Div Yield
- 2.94%
- Gross Margin
- 68.49%
- Op Margin
- 9.80%
- Net Margin
- 12.24%
- ROE
- 15.74%
- ROIC
- 6.58%
- Revenue
- $2.14T · 13.26%
- Net Income
- $261.51B · -11.58%
- EPS
- $140.61 · -9.84%
- Op Income
- $208.62B
- FCF YoY
- 61.93%
- 52W High
- $29.15
- 52W Low
- $13.85
- 50D MA
- $16.35
- 200D MA
- $20.12
- Beta
- -0.15
- Avg Volume
- 10.97K
Get TickerSpark's AI analysis on DSKYF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our DSKYF coverage
Recent articles, reports, and earnings notes.
No research on DSKYF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate DSKYF report →Similar companies
Peers in the same neighborhood.